Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telotristat ethyl in neuroendocrine tumors monitored by AMT-PET
NCT03453489Phase 2Completed
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Jun 2018
- Primary completion
- Oct 2020
- Countries
- 1
01
Overview
A Phase 2 trial of telotristat ethyl in Carcinoid Syndrome (CS), Neuroendocrine Neoplasm (NEN), sponsored by Barbara Ann Karmanos Cancer Institute. Started Jun 2018; status: completed.
02
Drugs
telotristat ethyl
03
Conditions
Carcinoid Syndrome (CS)Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT03453489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03453489.